The International Prognostic Index-Chronic Lymphocytic Leukemia (IPI-CLL) was used to assess risk stratification according to a number of prognostic markers, including age, B-CLL stage, IGHV status, 17p13 deletion, and β2 microglobulin level (Eichhorst et al. 2021). The gene discussed is HLA-G; the disease is B-cell chronic lymphocytic leukemia.